Patients diagnosed with metastatic melanoma with no previous medical intervention are administered a combination treatment consisting of relatlimab+nivolumab and nivolumab+ipilimumab, which involves the use of an anti-CTLA-4 monoclonal antibody. The gene discussed is CTLA4; the disease is metastatic melanoma.